Literature DB >> 31885838

The Long and Short of IT: intestinal failure-associated liver disease (IFALD) in adults-recommendations for early diagnosis and intestinal transplantation.

Jeremy Mark Woodward1, Dunecan Massey1, Lisa Sharkey1.   

Abstract

Intestinal failure-associated liver disease (IFALD) often presents in adults unexpectedly with advanced disease. Non-invasive tests can be falsely reassuring. Patients with 'ultrashort' intestine (<20 cm) ending in a stoma are at particular risk of developing IFALD, which may occur rapidly. Recent experience and studies suggest that IFALD can be reversed by isolated intestine transplant occurring before the development of high grade fibrosis or cirrhosis. Post-transplant survival is superior for isolated intestinal grafts compared with liver containing intestinal grafts; waiting time and waiting list mortality is higher for a combined graft, and donor liver supply is limited. Therefore, the aim of clinicians treating patients with intestinal failure should be to identify IFALD early and refer to an intestinal transplant centre while isolated intestine transplantation can be contemplated and before the liver disease has progressed to a stage requiring consideration of combined liver and intestinal transplantation. © Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  intestinal failure; intestinal transplantation; liver disease; parenteral nutrition; short bowel syndrome

Year:  2019        PMID: 31885838      PMCID: PMC6914300          DOI: 10.1136/flgastro-2018-101069

Source DB:  PubMed          Journal:  Frontline Gastroenterol        ISSN: 2041-4137


  31 in total

1.  Survival rate and prognostic factors in patients with intestinal failure.

Authors:  I Vantini; L Benini; F Bonfante; G Talamini; C Sembenini; G Chiarioni; O Maragnolli; F Benini; F Capra
Journal:  Dig Liver Dis       Date:  2004-01       Impact factor: 4.088

2.  Prevalence of liver complications in children receiving long-term parenteral nutrition.

Authors:  B Peyret; S Collardeau; S Touzet; I Loras-Duclaux; H Yantren; M C Michalski; J Chaix; L Restier-Miron; R Bouvier; A Lachaux; N Peretti
Journal:  Eur J Clin Nutr       Date:  2011-03-23       Impact factor: 4.016

3.  Ultra-short bowel is an independent risk factor for liver fibrosis in adults with home parenteral nutrition.

Authors:  Dominique Cazals-Hatem; Lore Billiauws; Pierre-Emmanuel Rautou; Vanessa Bondjemah; Nicolas Poté; Olivier Corcos; Valérie Paradis; Francisca Joly
Journal:  Liver Int       Date:  2017-09-02       Impact factor: 5.828

4.  Persistence of hepatic fibrosis in pediatric intestinal failure patients treated with intravenous fish oil lipid emulsion.

Authors:  Christina Belza; Rory Thompson; Gino R Somers; Nicole de Silva; Kevin Fitzgerald; Karen Steinberg; Glenda Courtney-Martin; Paul W Wales; Yaron Avitzur
Journal:  J Pediatr Surg       Date:  2017-01-30       Impact factor: 2.545

5.  Prevalence of liver disease and contributing factors in patients receiving home parenteral nutrition for permanent intestinal failure.

Authors:  M Cavicchi; P Beau; P Crenn; C Degott; B Messing
Journal:  Ann Intern Med       Date:  2000-04-04       Impact factor: 25.391

6.  Hepatic explant pathology of pediatric intestinal transplant recipients previously treated with omega-3 fatty acid lipid emulsion.

Authors:  Cal S Matsumoto; Stuart S Kaufman; Eddie R Island; Bhaskar Kallakury; Nada A Yazigi; Khalid M Khan; Thomas M Fishbein
Journal:  J Pediatr       Date:  2014-05-03       Impact factor: 4.406

7.  Prevalence and risk factors for complications in adult patients with short bowel syndrome receiving long-term home parenteral nutrition.

Authors:  Guohao Wu; Yi Jiang; Xiaoping Zhu; Dayong Jin; Yusong Han; Jun Han; Zhaohan Wu; Zhaoguang Wu
Journal:  Asia Pac J Clin Nutr       Date:  2017       Impact factor: 1.662

8.  Incidence, prognosis, and etiology of end-stage liver disease in patients receiving home total parenteral nutrition.

Authors:  S Chan; K C McCowen; B R Bistrian; A Thibault; M Keane-Ellison; R A Forse; T Babineau; P Burke
Journal:  Surgery       Date:  1999-07       Impact factor: 3.982

9.  Long-term follow-up of patients on home parenteral nutrition in Europe: implications for intestinal transplantation.

Authors:  Loris Pironi; Francisca Joly; Alastair Forbes; Virginie Colomb; Malgorzata Lyszkowska; Janet Baxter; Simon Gabe; Xavier Hébuterne; Manuela Gambarara; Frederic Gottrand; Cristina Cuerda; Paul Thul; Bernard Messing; Olivier Goulet; Michael Staun; André Van Gossum
Journal:  Gut       Date:  2010-11-10       Impact factor: 23.059

10.  Liver dysfunction associated with long-term total parenteral nutrition in patients with massive bowel resection.

Authors:  Y Ito; M E Shils
Journal:  JPEN J Parenter Enteral Nutr       Date:  1991 May-Jun       Impact factor: 4.016

View more
  4 in total

1.  A novel maladaptive unfolded protein response as a mechanism for small bowel resection-induced liver injury.

Authors:  Allie E Steinberger; Maria E Tecos; Hannah M Phelps; Deborah C Rubin; Nicholas O Davidson; Jun Guo; Brad W Warner
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2022-06-21       Impact factor: 4.871

2.  Serum Scoring and Quantitative Magnetic Resonance Imaging in Intestinal Failure-Associated Liver Disease: A Feasibility Study.

Authors:  Konstantinos C Fragkos; María Claudia Picasso Bouroncle; Shankar Kumar; Lucy Caselton; Alex Menys; Alan Bainbridge; Stuart A Taylor; Francisco Torrealdea; Tomoko Kumagai; Simona Di Caro; Farooq Rahman; Jane Macnaughtan; Manil D Chouhan; Shameer Mehta
Journal:  Nutrients       Date:  2020-07-19       Impact factor: 5.717

Review 3.  Home Parenteral and Enteral Nutrition.

Authors:  Jamie Bering; John K DiBaise
Journal:  Nutrients       Date:  2022-06-21       Impact factor: 6.706

Review 4.  Intravenous Lipid Emulsions in the Prevention and Treatment of Liver Disease in Intestinal Failure.

Authors:  Fedja A Rochling
Journal:  Nutrients       Date:  2021-03-10       Impact factor: 5.717

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.